Cytovale is a company focused on providing innovative diagnostic solutions for early detection of sepsis, a critical medical emergency. Their primary product, IntelliSep, is an FDA-cleared in vitro diagnostic test that helps healthcare providers quickly identify and risk-stratify patients in the emergency department who may be developing sepsis. By analyzing the immune response through the biomechanical properties of white blood cells, IntelliSep offers results in approximately 8 minutes, allowing for faster clinical decision-making and optimized patient outcomes. Cytovale aims to improve patient-centered care, operational efficiencies, and clinician satisfaction in emergency settings by complementing and enhancing traditional diagnostic methods with their rapid testing technology.